Intech Investment Management LLC Purchases Shares of 54,237 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Intech Investment Management LLC bought a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 54,237 shares of the biotechnology company’s stock, valued at approximately $412,000.

A number of other large investors have also made changes to their positions in the company. Deerfield Management Company L.P. Series C raised its holdings in shares of BioCryst Pharmaceuticals by 62.9% during the second quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company’s stock worth $50,279,000 after acquiring an additional 3,140,804 shares in the last quarter. Cubist Systematic Strategies LLC lifted its position in shares of BioCryst Pharmaceuticals by 528.0% in the second quarter. Cubist Systematic Strategies LLC now owns 1,112,232 shares of the biotechnology company’s stock worth $6,874,000 after buying an additional 935,132 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of BioCryst Pharmaceuticals by 1,058.1% in the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock valued at $3,127,000 after acquiring an additional 375,890 shares in the last quarter. Point72 Europe London LLP bought a new position in shares of BioCryst Pharmaceuticals in the 2nd quarter valued at approximately $1,654,000. Finally, TD Asset Management Inc bought a new stake in BioCryst Pharmaceuticals during the second quarter worth approximately $1,487,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Trading Down 1.6 %

BCRX opened at $7.38 on Tuesday. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.03 and a 1-year high of $8.88. The stock has a market capitalization of $1.53 billion, a PE ratio of -12.10 and a beta of 1.89. The firm has a 50-day moving average price of $7.59 and a two-hundred day moving average price of $7.32.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07). The firm had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. During the same period last year, the business posted ($0.19) earnings per share. The firm’s quarterly revenue was up 35.1% on a year-over-year basis. On average, research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on BCRX. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. JMP Securities boosted their target price on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. StockNews.com upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 6th. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $15.60.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.